BNP Paribas Financial Markets Increases Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

BNP Paribas Financial Markets boosted its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 9.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,560 shares of the biopharmaceutical company’s stock after buying an additional 6,574 shares during the quarter. BNP Paribas Financial Markets owned 0.13% of Sage Therapeutics worth $421,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. 683 Capital Management LLC boosted its holdings in Sage Therapeutics by 5.0% in the fourth quarter. 683 Capital Management LLC now owns 630,000 shares of the biopharmaceutical company’s stock valued at $3,421,000 after purchasing an additional 30,000 shares in the last quarter. Caligan Partners LP acquired a new stake in Sage Therapeutics in the fourth quarter valued at $16,575,000. Jane Street Group LLC grew its holdings in shares of Sage Therapeutics by 103.1% in the 4th quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company’s stock worth $2,509,000 after acquiring an additional 234,528 shares during the period. PDT Partners LLC grew its holdings in Sage Therapeutics by 37.2% in the fourth quarter. PDT Partners LLC now owns 235,097 shares of the biopharmaceutical company’s stock valued at $1,277,000 after purchasing an additional 63,804 shares during the last quarter. Finally, AdvisorShares Investments LLC increased its holdings in Sage Therapeutics by 104.9% during the 4th quarter. AdvisorShares Investments LLC now owns 47,800 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 24,470 shares in the last quarter. 99.22% of the stock is owned by institutional investors and hedge funds.

Sage Therapeutics Trading Down 1.2%

SAGE opened at $6.53 on Monday. Sage Therapeutics, Inc. has a twelve month low of $4.62 and a twelve month high of $13.47. The stock has a market cap of $408.92 million, a PE ratio of -0.99 and a beta of 0.20. The business’s 50 day moving average is $7.32 and its 200-day moving average is $6.74.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.02). The company had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The firm’s quarterly revenue was up 78.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.80) earnings per share. As a group, analysts forecast that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on SAGE shares. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research report on Friday, April 25th. HC Wainwright reiterated a “neutral” rating and set a $12.00 target price (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Bank of America began coverage on Sage Therapeutics in a report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 target price on the stock. Canaccord Genuity Group cut their price target on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, February 12th. Finally, Wedbush restated a “neutral” rating and issued a $6.00 target price on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Sage Therapeutics presently has an average rating of “Hold” and an average target price of $8.81.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.